Qki/PPARβ/RXRα (QPR) pathway activation for remyelination in multiple sclerosis

Overview

This research program targets a novel regulatory pathway—the Qki/PPARβ/RXRα (QPR) axis—to promote remyelination in multiple sclerosis (MS). Current MS therapies are largely immunomodulatory and manage symptoms without addressing the underlying failure to repair damaged myelin. The QPR approach addresses two fundamental obstacles to remyelination: the accumulation of uncleared myelin debris that blocks new oligodendrocyte recruitment, and the insufficient capacity of oligodendrocytes to produce the lipid components essential for myelin. By activating the QPR pathway, the technology simultaneously enhances microglial phagocytosis to clear myelin debris and boosts lipid biosynthesis in both existing and newly generated oligodendrocytes, offering a disease-modifying strategy rather than symptomatic relief.

Technical specifications

Key biological targets and mechanisms:

• Qki as a master regulator of both microglial phagocytosis and oligodendrocyte lipid metabolism
• Microglial activation through QPR agonism to clear myelin debris, creating a permissive environment for oligodendrocyte recruitment and differentiation
• Oligodendrocyte differentiation and myelin homeostasis driven by Qki-mediated coactivation of the PPARβ–RXRα transcription complex
• Transcriptional control of lipid metabolism genes identified through comparative lipidomic and transcriptomic analyses
• Brain-penetrant QPR agonists (KD3010 and bexarotene) validated in functional rescue experiments
• Dual-action therapeutic effect combining debris clearance with enhanced myelin lipid production

Technology readiness level

The program is currently at the preclinical validation stage. Foundational discoveries have established Qki as a critical regulator of microglial phagocytosis and oligodendrocyte lipid biosynthesis, with lipidomic and transcriptomic profiling confirming its role in myelin lipid production via PPARβ–RXRα coactivation. Functional rescue experiments using brain-penetrant QPR agonists KD3010 and bexarotene have provided initial proof-of-concept evidence. Planned future validation includes detailed investigation of QPR agonist KD3010 effects on microglial polarization, phagocytosis, cytokine secretion, and T cell modulation, as well as oligodendrocyte regeneration, myelin integrity, and the mechanistic basis of Qki coactivator function in both cell types. The approach is positioned for translational development toward MS therapeutics.